NanoXplore Announces Management and Board Changes

NanoXplore Inc. (" NanoXplore " or the " Company ") (TSX: GRA and OTCQX: NNXPF) announces today that after more than eight years with NanoXplore, Luc Veilleux, CFO, will be departing the Company from his position on July 18, 2022 and will be joining VoltaXplore as CFO. He will remain with the Corporation until September 1, 2022 to ensure a smooth transition. Luc has over 25 years of executive management, financial and operational experience in manufacturing and mining industries. His previous roles include CFO of Mason Graphite, President of Maxi Canada, and CFO of Imerys Graphite and Carbon. Mr. Veilleux, with his work ethic and talent, made a major contribution to NanoXplore's development.

"On behalf of everyone at NanoXplore, I'd like to express my gratitude to Luc for his outstanding leadership, selfless partnership, and financial stewardship. Luc has played a crucial role in NanoXplore's success and growth by helping lay the solid foundation that supports the company's innovation, global presence and financial strength. I am looking forward to continue working with Luc in VoltaXplore" said Soroush Nazarpour, President and CEO, NanoXplore.

"I'm deeply appreciative of the opportunity to have served as Chief Financial Officer of NanoXplore. The skills that I have strengthened working with NanoXplore have been invaluable, and I'm looking forward to transitioning to the next professional phase of my life" added Luc Veilleux.

APPOINTMENT OF NEW CFO, MR. PEDRO AZEVEDO

NanoXplore announces the appointment of Pedro Azevedo to the position of Chief Financial Officer effective July 18, 2022. Until recently, Mr. Azevedo was the CFO of Tarkett Sports, a division of publicly traded global manufacturing company Tarkett S.A. Prior to that, he occupied a variety of positions starting from a cost accountant to different corporate controller functions. Mr. Azevedo was instrumental at demonstrating his competency and leadership skills. He brings extensive experience in manufacturing, operations, and M&A. Mr. Nazarpour added, "I'm excited to welcome Pedro to NanoXplore. He is a high-impact executive who brings a compelling blend of operational and financial discipline. He will be a strong partner as we pursue our growth."

CHANGES TO THE BOARD OF DIRECTORS

Ms. Nathalie Pilon had resigned as board member of NanoXplore effective as of July 4, 2022, so that she may focus her efforts on other professional duties. The Company would like to extend heartfelt thanks to Ms. Pilon for her services. The Board of Directors together with the Company has initiated the search for a successor.

"On behalf of our Board, we thank Nathalie for her service and commitment to the Company, we greatly appreciate the leadership, insight, and expertise that Nathalie has provided since she joined." Commented Benoit Gascon, Lead Director of the Board of Directors of NanoXplore Inc.

ABOUT NANOXPLORE INC.

NanoXplore is a graphene company, a manufacturer and supplier of high-volume graphene powder for use in transportation and industrial markets. The Company provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors. NanoXplore is headquartered in Montreal, Quebec with manufacturing facilities across North America and Europe. Please visit www.nanoxplore.ca .

For further information, please contact:

Martin Gagné
Director, Investor Relations
martin.gagne@nanoxplore.ca
Tel: 438.476.1342


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

GRA:CA,NNXPF
Apex Resources

Apex Resources Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Apex Resources

Apex Resources

Strategic critical minerals assets in North America focused on tungsten and lithium

Strategic critical minerals assets in North America focused on tungsten and lithium Keep Reading...
Sona Nanotech

Sona Nanotech Grants Options

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has granted 25,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to a consultant. Each option is exercisable into one common share at a price of $0.30 per share... Keep Reading...
Sona Nanotech

Sona Nanotech

Get access to more exclusive Nanotech Investing Stock profiles here Keep Reading...
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Emerging Growth Virtual Conference taking place June 12-13, 2024. Details for the Company's presentation: Date: Wednesday, June 12, 2024 Time:... Keep Reading...
Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two... Keep Reading...
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI's Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cuts the 5-year risk... Keep Reading...

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide... Keep Reading...
Apex Resources

Apex Resources Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News